Edition:
United States

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

50.84USD
17 Aug 2018
Change (% chg)

$-0.58 (-1.13%)
Prev Close
$51.42
Open
$51.25
Day's High
$51.25
Day's Low
$50.31
Volume
215,900
Avg. Vol
348,197
52-wk High
$65.51
52-wk Low
$39.08

Select another date:

Fri, May 4 2018

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage:

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

Biogen to pay $1 billion to Ionis in new partnership

April 20 Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

UPDATE 1-Ionis may get up to $300 mln in licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Ionis to get up to $300 mln from licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.

BRIEF-Ionis And AstraZeneca Advance New Drug For NASH

* IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX

UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study

* Brokerage Suntrust estimates sales of $130 mln of drug in 2022

Select another date: